How Should You Read Company-Reported AI Research Results Like Anthropic's Drug-Discovery Claims?

How Should You Read Company-Reported AI Research Results Like Anthropic's Drug-Discovery Claims?

You should read them as hypotheses that have been well documented, not as findings that have been confirmed. In its October 27 drug-development update, Anthropic and six partners reported mostly preclinical results, and nearly all of them are self-reported. The update also announced Anthropic's acquisition of Mithril Medicine. Before accepting any of these numbers, check four things: what stage the evidence is at, who measured it, what it was compared against, and how big the sample was.

What did Anthropic actually claim?

Anthropic claimed early progress across seven efforts. Six are partner projects, and the seventh is a drug program it now owns. According to Anthropic's post, founder Cody Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 outside labs. He took a muscular dystrophy treatment from idea to promising mouse results in under 18 months. Anthropic says human trials could begin as early as late 2028 if the candidates keep holding up. Anthropic did not disclose deal terms.

The partner claims include:

• Enveda: Claude caught all 11 issues that human reviewers had found in 1,061 pages of manufacturing documents, plus seven more, and review time fell 89%.
• Generate Biomedicines: a CAR-T component about 70% shorter that produced roughly 10x more receptors in lab tests.
• Divergence Labs: about 35,000 antibody designs for food allergies, a few of which beat a standard drug in early assays.
• Bristol Myers Squibb: used Claude to assess clinical trial plans. No outcome data was reported, and the work is set to expand in 2027.

Which evidence tier is each result in?

Most of these results are at the lowest tiers of evidence. Sort each claim by stage before deciding how much weight it deserves:

1. In silico or design output. Examples are the 35,000 antibody designs and the Pleiades target-assessment skill, which has no published results. These show that Claude produced output, not that the output works.
2. In vitro or lab assay. Examples are the CAR-T receptor counts and the IgE displacement results. These are useful signals, but many drugs that work in assays fail later.
3. Animal model. Mithril's antibody is at this stage.
4. Human clinical data. None of the reported results are here.
5. Operational efficiency. Enveda's review-time cut fits here, and this is the tier where evidence is easiest to check. It measures work processes, not biology.

For context on the stage gap, Anthropic CEO Dario Amodei himself tempered expectations earlier this year, citing biology's slow timelines, STAT reported.

What does the Mithril data look like up close?

Up close, the Mithril data is a small, unreviewed pilot study. The company's own technical report is dated October 26 and is labeled as not peer reviewed. It reports that the stronger antibody format produced "about twice the peak force and grip strength" of untreated diseased mice after six weeks. The untreated comparison group had four mice, and the treatment groups had five and seven.

The report is candid about its weaknesses. The antibody's safety has not been established. The doses did not come from the same lots used in the lab tests. The mouse model also has nerve damage that patients don't have, which can distort hind-limb results. To its credit, the report includes a vehicle control and a gene-therapy comparison arm. Self-stated limits are a ceiling on confidence.

Who measured it, and against what?

In nearly every case, the people who measured the results are the same people who benefit from them. Anthropic wrote the summary, and the partners wrote the technical reports. Neither has been independently replicated. Ask three questions:

• Was there a baseline? Enveda's 89% figure compares against a human-review benchmark of more than 25 hours, which is a good sign. Several other claims give no comparison condition at all.
• Were the metrics fixed in advance? Anthropic says BigHat's team suspected partway through that standard stability metrics were misleading and proposed new ones. That may be good science, but changing metrics midway makes the results harder to interpret.
• Are the errors reported too? DigitalToday, citing ITmedia, reports that some Claude-written emails at Mithril listed antibody quantities incorrectly, and that at least three reached outside labs after human review. Disclosed failures make the rest of the account more credible.

Do the headlines match the sources?

The headlines simplify the sources in ways that matter. Coverage describes Mithril as a "one-person" biotech. DigitalToday says Tranbarger was the only full-time employee, and Endpoints News reports Atlas Venture backing. The actual experiments ran at 11 outside labs. Headcount figures also vary for Anthropic's earlier, reported ~$400 million Coefficient Bio deal: outlets cited six, nine, or fewer than ten staff. Treat labels as descriptions, not data.

What evidence checklist should you apply?

Apply this to any company-reported AI result, from a lab, a vendor or your own team:

1. Name the tier: design output, assay, animal, human, or operations.
2. Find the comparison: a control group, a baseline or a prior benchmark.
3. Count the sample: the number of animals, documents or campaigns.
4. Check pre-registration: whether the metrics were fixed before the results came in.
5. Look for independence: whether anyone outside the company has replicated the result.
6. Read the limitations section before the abstract.
7. Look for reported failures. A report with no errors at all deserves more scrutiny.

The same discipline applies to marketing measurement. A vendor's claim that its AI raised conversions has the same structure as a mouse study with four controls. Tools built around measurement, such as MarkGrid's Neuro-Marketing predictive creative testing, should be judged against a holdout or a prior baseline in the same way. When you research how AI assistants describe brands, Model Share tracks mentions and recommendations across models, and the GEO guide covers how to publish claims that those models can verify. For the full breakdown, see our MarkGrid analysis.